# Champions Oncology Announces a Multi-Year Agreement & Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies Canonical URL: https://biopharmsignal.com/news/CSBR/champions-oncology-announces-a-multi-year-agreement-strategic-collaboration-with-c65d8149 Ticker: CSBR Company: Champions Oncology Source: Champions Oncology Published: 2026-07-08 21:06 EST Original Source URL: https://blog.championsoncology.com/news ## Summary Aug 1, 2023 9:10:31 AM / by Champions Oncology HACKENSACK, NJ – August 1, 8:45AM - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global preclinical and clinical research services provider that offers end-... ## Article Body Aug 1, 2023 9:10:31 AM / by Champions Oncology HACKENSACK, NJ – August 1, 8:45AM - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions, today announced an agreement to adopt BioVolume's leading 3D imaging and thermal technology as their primary means of capturing efficacy results. Through this multi-year agreement Champions Oncology will incorporate BioVolume’s cutting-edge thermal and 3D imaging platform into its broad portfolio of in vivo preclinical offerings. In alignment with Champions' consistent focus on delivering the highest quality data and scientific excellence, the adoption of BioVolume technology will enable the achievement of greater accuracy, reduced variability, and the generation of reliable insights to advance oncology drug development programs across different therapeutic modalities. BioVolume is advancing global preclinical oncology by providing greater study accuracy and helping strengthen drug filings for clinical trials with a digital record of preclinical efficacy. Specifically, BioVolume detects, segments, and measures subcutaneous tumor growth in rodents. By providing traceable imaging for each volume measurement alongside the additional capture of tumor height, ensures greater reproducibility of study data and offers a statistically significant reduction in variability compared to calipers which rely on manual measurement. In silico modeling of BioVolume data demonstrates that reducing variability can decrease the chance of missing a therapeutic effect by a factor of seven in comparison to existing caliper-based processes. Maria Mancini, Chief Operating Officer at Champions Oncology said, “We are excited to announce our partnership with BioVolume. Adopting innovative technologies to digitize preclinical lab processes is critical to generating new breakthroughs in cancer research. The partnership will enable us to provide full transparency in study data collection and analysis, more accurate and consistent data, and greater scientific confidence to the pharma and biotech research community.” “Champions Oncology and BioVolume are both forward-looking companies committed to advancing science, and we look forward to working together to enable faster, smarter, and more confident decisions to be made in the identification and development of new cancer therapeutics,“ said Karl Turley, BioVolume Chief Operating Officer. “Cancer research is affected by a reproducibility crisis, and we believe our unique imaging platform will help tackle this challenge by transforming reproducibility in preclinical efficacy assessments.” ## Recent Company News - 2026-07-08 21:06 EST — [Champions Oncology Reports Quarterly Revenue of $13.1 Million](https://biopharmsignal.com/news/CSBR/champions-oncology-reports-quarterly-revenue-of-13-1-million-9f7e33ee) — Source: Champions Oncology - 2026-07-08 21:06 EST — [Champions Oncology Announces a Multi-Year Agreement & Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies](https://biopharmsignal.com/news/CSBR/champions-oncology-announces-a-multi-year-agreement-strategic-collaboration-with-c65d8149) — Source: Champions Oncology - 2026-07-08 21:06 EST — [Champions Oncology Announces Remarkable Lineup of Speakers at its Translational Oncology Symposium in Boston in September 2023](https://biopharmsignal.com/news/CSBR/champions-oncology-announces-remarkable-lineup-of-speakers-at-its-translational--c4916c08) — Source: Champions Oncology - 2026-07-08 21:06 EST — [News | Champions Oncology](https://biopharmsignal.com/news/CSBR/news-champions-oncology-349bd91b) — Source: Champions Oncology - 2026-07-08 21:06 EST — [Champions Oncology Reports Quarterly Revenue of $12.6 Million](https://biopharmsignal.com/news/CSBR/champions-oncology-reports-quarterly-revenue-of-12-6-million-484f1741) — Source: Champions Oncology ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) - 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)